Quarterly report pursuant to Section 13 or 15(d)

Subsequent events (Details)

v3.21.2
Subsequent events (Details) - Strategic Collaboration and License Agreement
$ in Millions
Sep. 03, 2021
USD ($)
item
Number of therapies to be co-developed | item 2
Number of co-development targets | item 5
Initial period of collaborated research 8 years
Number of additional terms | item 2
Number of additional years 2 years
Number of years payments are due 5 years
Upfront payment received $ 150
Milestone payments 150
Development Milestone | Maximum  
Milestone payments 200
Development Milestone - Off The Shelf Member T-cell Therapies | Maximum  
Milestone payments 100
Research Milestone | Maximum  
Milestone payments $ 50
Commercialisation Milestone  
Number of co-development targets | item 5
Commercialisation Milestone | Maximum  
Milestone payments $ 1,100
Sales Milestone  
Number of co-development targets | item 5
Sales Milestone | Maximum  
Milestone payments $ 1,500
Regulatory, Sales, And Royalties Milestones | Maximum  
Milestone payments $ 800